Does Wegovy Target Belly Fat? Exploring Its Impact on Weight Loss

Last reviewed: June 26, 2026

Last updated: June 26, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide works by slowing gastric emptying and signaling satiety in the brain, helping patients lose an average of 15-22% of body weight over 68 weeks in clinical trials. While weight loss occurs throughout the body, research suggests GLP-1 receptor agonists may have a particular effect on hazardous visceral fat stored around organs—the type most linked to metabolic disease and cardiovascular risk.

How Semaglutide Promotes Overall Weight Loss

Semaglutide activates GLP-1 receptors in the hypothalamus, a brain region controlling hunger and energy expenditure. This activation reduces appetite signals and increases feelings of fullness after smaller meals, naturally lowering daily calorie intake without extreme dietary restriction. The medication also slows how quickly food moves through your stomach, prolonging satiety between meals.

Clinical evidence shows patients on semaglutide lose weight consistently across multiple body regions over time. A 2023 analysis of Novo Nordisk trials found that study participants experienced reductions in total body weight, lean muscle loss remained minimal, and metabolic rate stabilization occurred—meaning weight loss came primarily from fat stores rather than muscle breakdown.

Visceral Fat Reduction: Why Belly Fat Matters Most

Visceral fat differs from subcutaneous fat (the pinchable layer under skin) because it wraps around abdominal organs and produces inflammatory compounds linked to insulin resistance, type 2 diabetes, and heart disease. Studies show that reducing visceral fat—even without major changes in total weight—improves cholesterol, blood pressure, and glucose control. This is why two people with the same BMI can have vastly different health outcomes based on where their fat is stored.

Research on GLP-1 therapy suggests these medications may preferentially reduce visceral fat deposits. A 2022 study in Obesity found that patients receiving semaglutide showed greater reductions in visceral adipose tissue relative to subcutaneous fat compared to placebo groups, meaning the medication may target the most dangerous fat first. This mechanism likely occurs because visceral adipose tissue expresses higher concentrations of GLP-1 receptors than subcutaneous tissue.

Individual Response Variation and Genetic Factors

Not every patient responds identically to semaglutide—some lose weight rapidly and preferentially from the abdomen, while others experience more distributed weight loss. Genetic variations influence how efficiently your body processes GLP-1 signaling and metabolizes stored fat. PlexusDx Precision Peptide Genetic Test analyzes 14 metabolic pathways and 49 peptide-related genes, including the GLP1R rs6923761 variant, which correlates with individual semaglutide response patterns and fat distribution changes.

The FTO rs9939609 variant, associated with appetite regulation and fat storage preference, and the MC4R rs17782313 variant, linked to satiety signaling, both influence how your body distributes weight loss across belly and other regions. Understanding your genetic profile helps PlexusDx clinicians predict whether you'll respond optimally to standard semaglutide dosing or benefit from adjunctive therapies like the Microdose GLP-1 Protocol or dual-compound GLP-Squared formulations that address multiple appetite pathways simultaneously.

PlexusDx Semaglutide: Personalized Dosing Without Price Escalation

PlexusDx Compounded Semaglutide Injection starts at $149 per month across all commitment tiers, with doses that scale up as your treatment progresses without increasing your monthly cost. This flat-rate pricing model removes barriers to treatment optimization—your dose may need to go up as your body adapts, but your price won't change. The medication comes from licensed 503A compounding pharmacies, ensuring pharmaceutical-grade purity and consistency.

All semaglutide therapy through PlexusDx is HSA/FSA eligible, requires no insurance, and serves all 50 states. After your first month of treatment, you can add the Precision Peptide Genetic Test ($99 one-time) to map your individual response profile and refine your therapeutic approach. This combination of affordability, accessibility, and personalization addresses the reality that effective weight loss—especially targeted visceral fat reduction—requires both the right medication and the right dose for your unique biology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Does semaglutide specifically target belly fat over other areas?

Research suggests semaglutide may preferentially reduce visceral belly fat because this tissue expresses higher GLP-1 receptor density than subcutaneous fat. However, meaningful weight loss occurs throughout the body, and individual fat distribution patterns depend on genetics, baseline body composition, and medication response. PlexusDx Precision Peptide Genetic Test identifies your GLP1R variants to predict how your body will respond.

How much belly fat can be lost with semaglutide therapy?

Clinical trials show semaglutide produces 15-22% total body weight loss over 68 weeks, with visceral fat reductions occurring earlier in treatment than subcutaneous fat loss. The absolute amount depends on your starting weight, adherence, and genetic metabolism profile. Patients typically notice abdominal circumference reductions within 8-12 weeks as visceral deposits shrink first.

What is the cost of semaglutide through PlexusDx?

PlexusDx Compounded Semaglutide Injection starts at $149 per month on any commitment tier, with no your dose may need to go up - your price won't adjusts upward. HSA/FSA funds cover this therapy, no insurance is required, and service extends to all 50 states. After one month, add the Precision Peptide Genetic Test for $99 to personalize your ongoing care.

Are compounded semaglutide injections as effective as brand-name Wegovy?

PlexusDx sourced semaglutide comes from licensed 503A compounding pharmacies meeting strict pharmaceutical standards, though compounded medications are not FDA-approved in the same way as brand products. Clinical evidence supports GLP-1 efficacy broadly across formulation sources. Bioequivalence and purity depend on pharmacy quality—PlexusDx partners exclusively with licensed 503A facilities to ensure consistency.

How does the Precision Peptide Genetic Test improve semaglutide results?

PlexusDx Precision Peptide Genetic Test maps 14 metabolic pathways and analyzes variants like GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 that predict individual semaglutide response and fat distribution patterns. This $99 genetic profile, added after your first treatment month, allows clinicians to optimize your dose, predict visceral fat loss timing, and recommend combination therapies if needed for maximal belly fat reduction.

Related Reading

• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss
• Wegovy Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.